It's been a great morning session for Genmab A/S ADS investors, who saw their shares rise 4.5% to a price of $33.56 per share. At these higher prices, is the company still fairly valued? If you are thinking about investing, make sure to check the company's fundamentals before making a decision.
The Market May Be Undervaluing Genmab A/S ADS's Assets and Equity:
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 22.94 and an average price to book (P/B) ratio of 3.19. In contrast, Genmab A/S ADS has a trailing 12 month P/E ratio of 17.4 and a P/B ratio of 0.39.
Genmab A/S ADS has moved 43.2% over the last year compared to 17.9% for the S&P 500 — a difference of 25.3%. Genmab A/S ADS has a 52 week high of $33.61 and a 52 week low of $17.23.
Exceptional EPS Growth and an Excellent Current Ratio:
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue (M) | $5,366 | $10,111 | $8,417 | $14,505 | $16,474 | $21,526 |
| Operating Margins | 49% | 62% | 35% | 43% | 32% | 31% |
| Net Margins | 40% | 47% | 35% | 38% | 26% | 36% |
| Net Income (M) | $2,166 | $4,758 | $2,957 | $5,452 | $4,352 | $7,844 |
| Net Interest Expense (M) | $221 | -$409 | $965 | $678 | $316 | $2,461 |
| Earnings Per Share | $34.03 | $72.21 | $44.77 | $82.59 | $66.02 | $121.36 |
| EPS Growth | n/a | 112.2% | -38.0% | 84.48% | -20.06% | 83.82% |
| Free Cash Flow (M) | $1,326 | $6,433 | $2,228 | $3,912 | $7,380 | $7,771 |
| Current Ratio | 14.88 | 15.0 | 14.44 | 15.48 | 13.34 | 5.25 |
Genmab A/S ADS has exceptional EPS growth, generally positive cash flows, and an excellent current ratio of 5.25. Furthermore, Genmab A/S ADS has decent operating margins with a negative growth trend.
